Vitamin U (S-Methylmethionine): A Comprehensive Reference
1. Identity, Nomenclature, and Classification
"Vitamin U" is a common name for S-methylmethionine (SMM), also referred to in the literature as methylmethionine sulfonium chloride (MMSC). It is a methylated derivative of the essential amino acid methionine and belongs to the class of sulfonium compounds. Vitamin U is a highly active compound but may not have any essential function in the body; it is a name given to MMSC, a molecule with many biological activities, but it does not have an essential function and is not currently accepted as a true vitamin.
S-Methylmethionine, characterized by the chemical formula C₆H₁₄NO₂S⁺, is typically encountered as the chloride salt (C₆H₁₄ClNO₂S). This compound features a positively charged sulfur atom methylated at the thioether group of methionine, making it a key intermediate in sulfur assimilation pathways. The full chemical formula of the SMM cation is (CH₃)₂S⁺CH₂CH₂CH(NH₃⁺)CO₂⁻. The IUPAC name is (3-amino-3-carboxypropyl)dimethylsulfonium; the compound is also listed under the synonyms S-methyl-L-methionine, 3-amino-3-carboxypropyl dimethylsulfonium, and, in commercial/pharmaceutical contexts, by trade names including U-Vit and Vitamin U Chloride. The CAS registry number for the chloride salt is 1115-84-0.
S-methylmethionine is sometimes referred to as vitamin U, but it is not considered a true vitamin. The term was coined in 1950 by Garnett Cheney for uncharacterized anti-ulcerogenic factors in raw cabbage juice that may help speed healing of peptic ulcers. S-methylmethionine was called vitamin U from the Latin ulcus — ulcer — because it inhibited ulceration in the digestive system.
1.1 Common Names and Synonyms
- Vitamin U
- S-Methylmethionine (SMM)
- Methylmethionine sulfonium chloride (MMSC)
- S-Methyl-L-methionine sulfonium chloride
- 3-Amino-3-carboxypropyl dimethylsulfonium
- DL-Methionine methylsulfonium chloride (older pharmaceutical literature)
1.2 Pharmacopeial and Regulatory Status
Vitamin U is a synonym for methylmethionine sulfonium chloride. It is an important natural factor in raw cabbage juice that supports gastric health. In Japan, it is used in over-the-counter pharmaceutical products and is listed in the Japanese Pharmaceutical Codex and the Japanese Pharmacopoeia. In the United States, it is marketed as a dietary supplement and does not carry FDA approval as a drug for any indication.
2. Natural Sources and Distribution
S-Methylmethionine occurs widely in plants, including cruciferous vegetables like cabbage and broccoli, as well as tomatoes, celery, spinach, garlic, and corn, where it serves as a major form of organic sulfur transport in phloem sap, facilitating sulfur distribution from source to sink tissues and supporting methionine biosynthesis through demethylation.
S-methylmethionine is not synthesized in the human body and must come from food sources, including white cabbage and its juice, asparagus, broccoli, fresh potato juice, carrots, celery, beets, parsley and dill, green onion, tomatoes, bananas, green tea, raw egg yolks, raw milk, and liver.
SMM is commonly found in plants such as cabbage, broccoli, wheat, and sunflowers. Although its biological role in plants is not well understood, SMM is known to preserve methionine, serve as a methyl donor, and regulate S-adenosylmethionine (SAM).
S-methylmethionine is particularly abundant in plants, being more abundant than methionine itself. Importantly, SMM is heat-sensitive; cooking substantially degrades the compound, which is why studies have consistently emphasized raw cabbage juice as the bioactive preparation. S-methylmethionine and different amino acids have also been identified in various types of tea, including green tea, black tea, and in Chinese cabbage and red cabbage extracts.
3. Biosynthesis and Plant Physiology
S-methylmethionine is biosynthesized from L-methionine and S-adenosylmethionine by the enzyme methionine S-methyltransferase. SMM is a derivative of L-methionine catabolism, which is first methylated to S-adenosylmethionine (SAM), and then the adenosyl group is replaced by a methyl group catalyzed by the enzyme methionine S-methyltransferase, making this molecule a potent methyl donor.
In plant physiology, S-methylmethionine plays an essential role in sulfur metabolism by acting as a stable, non-toxic sulfur donor that enhances sulfur partitioning, seed set, and overall nutrient efficiency. Engineering a plant-derived MMT gene encoding methionine S-methyltransferase into Saccharomyces cerevisiae has enabled microbial production of SMM, demonstrating ongoing biotechnological interest in the compound.
4. Historical and Traditional Use
4.1 European Folk Medicine
Long before its isolation as a specific compound, cabbage and its juice had been used in European folk medicine for treating stomach ailments, indigestion, and inflammation. In traditional herbal texts, raw cabbage was often recommended for both internal ulcerations and external wounds, reflecting a broader recognition of its tissue-repairing effects.
4.2 Modern Clinical Discovery: Garnett Cheney (1940s–1950s)
One of the landmark studies occurred in the 1940s when Dr. Garnett Cheney, a Stanford University medical professor, treated 13 patients suffering from peptic ulcers with fresh cabbage juice. Each patient consumed one liter of juice daily. Many experienced complete healing within 7 to 10 days — a notable improvement compared to the 30-day recovery period using standard therapy at the time.
These results came from the 1950s, when peptic ulcers frequently caused bleeding from the ulcer, perforation of the stomach and duodenum, and even death. At the time, the cause of peptic ulcers was not well understood, and it was believed that a heat-sensitive substance in cruciferous vegetables like cabbage protected against peptic ulcers. This unidentified substance, now known to be MMSC, was named vitamin U.
Cheney's body of research comprised several distinct clinical publications. Thirteen patients with peptic ulcer were treated with fresh cabbage juice, which, experiments had indicated, contains an antipeptic ulcer factor. This factor (vitamin U) was also shown to prevent the development of histamine-induced peptic ulcers in guinea pigs. In a 1956 study conducted at San Quentin Prison, a clinical study was undertaken to evaluate the effectiveness of concentrated cabbage juice in the treatment of peptic ulcers. Patients with a diagnosed ulcer crater were treated in a double-blind control experiment given either concentrated cabbage juice or a placebo facsimile. The evaluation was based upon repeated X-ray examinations of the ulcer crater. A period of 22 days was allowed for ulcer crater healing time. The results of this experiment indicated concentrated cabbage juice to be effective in the healing of peptic ulcer.
Interest in SMM arose in the mid-twentieth century due to observations of accelerated healing of gastric ulcerations upon consumption of plant-derived foods rich in this factor, which gave rise to the term "vitamin U." Subsequently, the transition from the phenomenological concept of "vitamin U" to a pharmacologically characterized compound was described in detail by Soviet researchers. In the review article by Tumanov and Chekman, SMM was presented as an activated form of methionine with a high methyl potential, supposedly exceeding methionine itself in its capacity for methyl group donation. The authors summarized experimental and clinical data indicating the antiulcer action of the drug, stimulation of regenerative processes in the gastric mucosa, possible reduction of gastric acidity, normalization of hepatic function, and effects on lipid metabolism.
5. Key Constituents, Active Compounds, and Mechanisms of Action
5.1 Core Biochemical Identity
Vitamin-like compound S-methyl-L-methionine (SMM) is a metabolic agent that affects metabolic processes, causing a wide variety of effects. Data from studies demonstrate a gastroprotective effect, hypolipidemic and antioxidant effects, and participation in regulation of adipocyte function and homocysteine exchange. SMM is involved in all methylation reactions in which another activated form of methionine, S-adenosylmethionine, normally participates.
SMM may participate in all methylation reactions using SAM as another activated form of methionine. SAM is an inhibitor of the most important enzyme of the methylation system, which completes the formation of methyl radicals from one-carbon compounds, restoring the methylene group of folates to methyl. Since SAM has an inhibitory effect on the system of xenobiotic metabolism in the liver while S-methylmethionine does not affect the functional activity of the liver's isoenzymes and does not have an inhibitory effect on methylation processes, the use of S-methylmethionine is considered preferable and safe as a nutrient.
5.2 Gastroprotective Mechanisms
The mechanism of Vitamin U is thought to involve the stimulation of mucin production, protection of epithelial cells, and modulation of local inflammation. The active component believed to accelerate ulcer recovery is S-methylmethionine, or "vitamin U." It boosts mucus production, helping the digestive tract rebuild itself and form a protective barrier against stomach acid and irritants.
Experimental studies have demonstrated that ulcer formation in patients and experimental models is accompanied by hypergastaminemia, accumulation of histamine in the gastric mucosa, and pronounced edematous-congestive changes in tissues. The ability of SMM to counteract these changes is a proposed basis for its gastroprotective activity.
5.3 Anti-Inflammatory Mechanisms
Tests conducted on mice demonstrated that methylmethionine-sulfonium chloride (vitamin U) is capable of lowering the permeability of the skin capillaries following the action of stimulants. It greatly potentiates the antiphlogistic (anti-inflammatory) effect of acetylsalicylic acid, with this action being more pronounced when vitamin U is administered one hour before intake of acetylsalicylic acid than when both are taken simultaneously. At a dose of 1000 mg/kg, vitamin U helps reduce exudation in aseptic serositis in rats. The antiphlogistic effect of vitamin U comes in conjunction with its ability to exercise a protective action against lesion of the gastric mucosa produced by acetylsalicylic acid. These findings are based on animal models.
5.4 Antioxidant Mechanisms
Gessler et al. reported that vitamin U can decrease the level of lipid peroxidation and inhibit monoamine oxidase activity. They also reported that vitamin U has a hypolipidemic effect. Despite the small number of articles and research studies, the notable antioxidant and anti-inflammatory properties of this substance, along with its extensive range of target organs and tissues and its low toxicity, position it as a promising candidate for the development of novel medicines.
5.5 Methylation Chemistry and SAM Cycle
SMM is a derivative of L-methionine catabolism, first methylated to S-adenosylmethionine (SAM), which then donates methyl groups to targets ranging from proteins and nucleotides to carbohydrates — processes affecting a large number of biological processes. At normal concentrations in the liver, SAM also directs homocysteine toward remethylation to reestablish metabolic homeostasis. The structural analogy between SMM and SAM means SMM can function as an alternative methyl donor across many of the same reactions.
6. Scientific Evidence by Area of Use
6.1 Peptic Ulcer Disease
Traditional/Early Clinical Evidence: Thirteen patients with peptic ulcer were treated with fresh cabbage juice. This factor (vitamin U) was shown to prevent the development of histamine-induced peptic ulcers in guinea pigs. The average crater healing time for seven of these patients who had duodenal ulcer was only 10.4 days, while the average time as reported in the literature, in 62 patients treated by standard therapy, was 37 days. The average crater healing time for six patients with gastric ulcer treated with cabbage juice was only 7.3 days, compared with 42 days, as reported in the literature, for six patients treated by standard therapy.
Limitations of Early Studies: Cheney's pioneering studies had small sample sizes (13 patients in the 1949 report), lacked randomization in the earliest iterations, and used raw cabbage juice — a complex mixture containing not only SMM but glutamine and other bioactive compounds — rather than isolated SMM. These constraints make attribution of effects to SMM alone difficult. The initial study, entitled "Rapid Healing of Peptic Ulcers in Patients Receiving Fresh Cabbage Juice," was considered of inadequate interest by the medical establishment to make these experiences better known.
Later Controlled Evidence: A later clinical study at San Quentin Prison evaluated concentrated cabbage juice in the treatment of peptic ulcers in a double-blind control experiment. Patients with a diagnosed ulcer crater received either concentrated cabbage juice or a placebo facsimile, and the evaluation was based on repeated X-ray examinations over 22 days. Results indicated concentrated cabbage juice to be effective in healing of peptic ulcer. This 1956 study (Cheney, Waxler, and Miller, California Medicine, 84(1):39–42) remains among the more methodologically rigorous of the early reports, though it still studied cabbage juice rather than the isolated compound.
Evidence Strength: For peptic ulcer, evidence from the Cheney-era clinical work is preliminary and historically significant but methodologically limited by today's standards. No large-scale, randomized controlled trials using isolated MMSC for peptic ulcer disease have been published in the peer-reviewed literature.
6.2 Chronic Gastritis and Dyspepsia
S-methylmethionine is a metabolic substrate that affects many metabolic processes in the human organism. Since its discovery, a large number of studies have demonstrated its safety and effectiveness in various diseases, especially diseases of the gastrointestinal tract. One study's purpose was to evaluate the effect of methylmethionine sulfonium chloride intake on the symptoms of dyspepsia and the quality of life of patients with chronic gastritis.
This study included 37 patients (21 men and 16 women) aged 35–60 years with chronic gastritis of various etiologies. All patients were prescribed S-methylmethionine at a dose of 300 mg per day. Clinical manifestations of dyspepsia were assessed using the GSRS questionnaire, and quality of life was assessed using the SF 36 questionnaire. The survey was conducted before the start of therapy, and after 3 and 6 months.
By the third month, a statistically significant decrease in the total GSRS score was observed, with scores averaging 9 points (p < 0.05) among all patients. By the sixth month, the total GSRS score averaged 5.5 points (p < 0.05). By the end of the 3rd month of therapy, indicators such as physical functioning, bodily pain, and social functioning improved (SF-36). By the end of the 6th month, several other indicators also improved, including role-physical functioning, general perception of health, vitality, role-emotional functioning, and mental health (p < 0.05).
A separate retrospective non-interventional study examined a real-world clinical population. An anonymous, retrospective, non-interventional clinical study included 408 patients with a primary diagnosis of dyspepsia (K30.0) treated with a combination of omeprazole (20 mg) and methylmethionine sulfonium chloride (300 mg) or omeprazole (20 mg) alone for 30 days for epigastric pain syndrome.
Evidence Strength: The chronic gastritis evidence is preliminary-to-moderate. The 37-patient study (Drozdov et al., 2023) is uncontrolled (no placebo arm) and conducted in a single-center Russian academic setting. While statistically significant improvements in validated symptom and quality-of-life instruments were reported, the lack of a randomized control group makes definitive causation uncertain.
6.3 Lipid Metabolism and Hypolipidemic Effects
The hypolipidemic and anti-atheromatous effects of MMSC were investigated using various experimental procedures. Orally administered MMSC markedly normalized dietary-induced hyperlipidemia in rats and rabbits, demonstrating lowering effects on plasma total cholesterol, beta-lipoprotein, and phospholipids, with no appreciable effect on plasma triglycerides. In normolipidemic and surfactant-induced hyperlipidemic rats, MMSC did not decrease plasma lipid levels.
S-Methylmethionine dose-dependently lowered increased plasma LDL and normalized decreased HDL in dietary-induced hyperlipidemic rats.
The effects of MMSC on aminonucleoside-induced nephrotic hyperlipidemia in rats were investigated. Repeated oral administration of MMSC at a dose of 1,000 mg/kg daily exhibited significant amelioration of plasma cholesterol and phospholipid levels. The treatment also improved nephrotic syndrome itself by producing an increase of urinary volume and a decrease of urinary protein excretion. Results suggest that MMSC may be useful as single or combined therapy for human nephrotic syndrome and its related hyperlipidemia.
A human study on lipids is also referenced in the literature. The study "Hypolipidemic effect of L-form S-methylmethionine sulfonium chloride in man" was published by Nakamura N et al. in Arzneimittelforschung 1981;31(4):725–9.
Evidence Strength: The hypolipidemic evidence is predominantly preclinical (animal models). The one human study from 1981 is older, has limited methodological detail available from modern secondary sources, and has not been replicated or extended in modern clinical trials. Findings should be considered hypothesis-generating rather than established.
6.4 Wound Healing and Dermal Repair
Skin wounds are accompanied by mucosal erosion and share similar histopathological aspects with gastric ulcers, so it is plausible that SMMS may promote skin wound healing. SMMS is a derivative of the amino acid methionine, synthesized in a variety of plants. In animal models, topical administration of SMMS for a given period of time, to both physical and chemical wounds, facilitated wound closure and promoted re-epithelialization compared with a control.
A key mechanistic study identified the intracellular pathway responsible: Kim WS, Yang YJ, et al., in a study titled "Accelerated wound healing by S-methylmethionine sulfonium: evidence of dermal fibroblast activation via the ERK1/2 pathway," published in Pharmacology 2010;85(2):68–76 (PMID 20110751), demonstrated that SMMS activates dermal fibroblasts via the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway. The topical administration of SMM enhanced the repair of skin damage by activation of fibroblasts, thereby showing a wound healing effect.
S-methyl-L-methionine (SMM), also known as vitamin U, is commercially available as a skin care cosmetic product for its wound healing and photoprotective effects. However, the low skin permeation expected of SMM due to its hydrophilic nature with a log P value of −3.3 has not been thoroughly addressed. Research into permeation enhancers has shown that among the enhancers tested, oleic acid showed the most significant enhancing effect on in vitro skin permeation and deposition of SMM.
SMM also showed a photoprotective effect by reducing UV-induced skin damage.
Evidence Strength: The wound-healing evidence is largely preclinical (cell culture and animal models). SMM is incorporated into cosmetic formulations based on these findings, but robust, double-blind, placebo-controlled clinical trials confirming wound-healing or photoprotective benefits in humans are not yet available in peer-reviewed literature.
6.5 Hepatoprotection (Liver Protection)
Vitamin U prevents valproic acid-induced liver injury through supporting the enzymatic antioxidant system and increasing hepatocyte proliferation triggered by inflammation and apoptosis. This was demonstrated in animal research: Ertan Celik et al., "Vitamin U prevents valproic acid-induced liver injury through supporting enzymatic antioxidant system and increasing hepatocyte proliferation triggered by inflammation and apoptosis," Toxicology Mechanisms and Methods 2021;31(8):600–608.
Protective effects of SMMS in valproic acid-induced liver and kidney injury have been reported.
Evidence Strength: Preclinical only. Hepatoprotective effects have been demonstrated in rodent models of drug-induced liver injury (particularly valproic acid toxicity), but no controlled human clinical trials have established hepatoprotective efficacy or dosing in humans.
6.6 Adipocyte Differentiation and Potential Anti-Obesity Effects
S-methylmethionine sulfonium chloride was originally called vitamin U because of its inhibition of ulceration in the digestive system. Vitamin U is ubiquitously expressed in the tissues of flowering plants, and while there have been reports on its hypolipidemic effect, its precise function remains unknown. A study was designed to evaluate the anti-obesity effect of vitamin U in 3T3-L1 pre-adipocyte cell lines.
The study was conducted to determine whether vitamin U can modulate differentiation in 3T3-L1 adipocytes. The involvement of glycerol-3-phosphate dehydrogenase (G3PDH), AMP-activated protein kinase (AMPK), and adipocyte-specific markers (PPAR-γ, C/EBP-α, ADD-1, adipsin, FAS, and LPL) were evaluated. This cell-culture study was published in Annals of Dermatology 2012;24(1):39–44.
Evidence Strength: In vitro (cell culture) only. Inhibition of adipocyte differentiation in a cell line does not translate directly to anti-obesity effects in humans. No clinical evidence exists for this application.
6.7 Broader Cytoprotective and Organ-Protective Effects (Preclinical)
The most consistently reported effects include gastroprotective and antiulcer activity, as well as antioxidant, anti-inflammatory, cytoprotective, and regenerative activities — these are observed predominantly in preclinical studies. Particular attention has been paid to organ-specific protection in the nervous system, liver, kidneys, lungs, skin, eyes, and oral tissues, although human evidence remains scarce.
Reviews have noted pleiotropic pharmacological effects of MMSC, commonly referred to as vitamin U, with important pharmacological protective effects documented for various organs, including the stomach, liver, kidneys, skin, eyes, and brain.
7. Body Systems and Health Areas Associated with Vitamin U
- Gastrointestinal system: Vitamin U is best known for its ability to protect and repair the lining of the gastrointestinal tract, particularly the stomach and duodenum. It has been studied primarily for the treatment and prevention of peptic ulcers, gastritis, acid reflux, and mucosal inflammation.
- Cardiovascular/lipid metabolism: Studied in rodent models for effects on cholesterol fractions and phospholipids; one older human study published in Arzneimittelforschung (1981) examined lipid effects in humans.
- Skin and wound healing: SMM, also known as vitamin U, is commercially available as skin care cosmetic products for its wound healing and photoprotective effects.
- Liver: Preclinical data support hepatoprotective potential, particularly against drug-induced toxicity.
- Kidney: Protective effects of SMMS in valproic acid-induced kidney injury have been reported.
- One-carbon / methylation metabolism: SMM is involved in all methylation reactions in which another activated form of methionine, S-adenosylmethionine, normally participates.
8. Dosage Forms and Reported Dosages
8.1 Food Sources
Cheney's initial study used a litre of raw cabbage juice consumed throughout each day. Based upon the results of the studies, the authors appear to suggest a protocol lasting 10–13 days. The large volume of raw cabbage juice per day was the vehicle used in the early uncontrolled and double-blind clinical studies.
8.2 Oral Supplement Forms
Sources of methylmethionine sulfonium chloride include raw cabbage, broccoli, Brussels sprouts, celery, and spinach, with supplements typically derived from cabbage extracts or synthetic equivalents. Supplement forms include tablets, capsules, and powder preparations of MMSC, frequently standardized to the chloride salt form.
8.3 Dosages Reported in Studies
- 300 mg/day (oral, human): In the 2023 chronic gastritis study, all patients were prescribed S-methylmethionine at a dose of 300 mg per day. This is also the dosage used in the retrospective dyspepsia study examining MMSC combined with omeprazole.
- 1,000 mg/kg/day (oral, rat): In nephrotic hyperlipidemia animal research, repeated oral administration of MMSC at a dose of 1,000 mg/kg daily exhibited significant amelioration of plasma cholesterol and phospholipids levels.
- 1,000 mg/kg (oral, rodent, anti-inflammatory): In anti-inflammatory rodent research, a dose of 1,000 mg/kg vitamin U helped reduce exudation in aseptic serositis in rats.
8.4 Topical / Cosmetic Forms
Vitamin U is available not only as a supplement but also found naturally in various foods; additionally, cosmetics companies add it to certain creams, serums, face masks, and other products. Research into the use of permeation enhancers such as oleic acid and ethanol has been conducted to overcome the poor topical absorption of the highly hydrophilic molecule.
9. Safety Considerations and Known Interactions
9.1 General Toxicological Profile
Soviet-era reviews summarized experimental and clinical data indicating the antiulcer action of the drug, stimulation of regenerative processes in the gastric mucosa, possible reduction of gastric acidity, normalization of hepatic function, and effects on lipid metabolism. The work also highlighted the low toxicity of SMM.
Despite the small number of articles and research studies, the notable antioxidant and anti-inflammatory properties of this substance, along with its extensive range of target organs and tissues and its low toxicity, position it as a promising candidate for the development of novel medicines.
9.2 Stability and Heat Degradation
SMM is a hygroscopic compound and is notably heat-labile. This is pharmacologically significant: cooking vegetables destroys the compound, explaining why Cheney's studies specifically required raw cabbage juice and why modern preparations are typically derived from dried, non-heat-processed extracts or from synthetic routes. Biopharmaceutical limitations related to stability were discussed as a relevant constraint in the pharmacological characterization of SMM.
9.3 Reported Adverse Effects
S-methylmethionine is a metabolic substrate that affects many metabolic processes in the human organism. Since its discovery, a large number of studies have demonstrated its safety and effectiveness in various diseases. In the 2023 chronic gastritis study at 300 mg/day over six months, no safety-related adverse events were specifically flagged in the available abstract data, and the study characterized its use as safe. Rat model studies suggested that MMSC may be useful as single or combined therapy for human nephrotic syndrome and its related hyperlipidemia as a safety drug.
9.4 Interaction with Omeprazole / Proton Pump Inhibitors
A retrospective non-interventional clinical study included 408 patients with a primary diagnosis of dyspepsia treated with a combination of omeprazole (20 mg) and methylmethionine sulfonium chloride (300 mg), or omeprazole (20 mg) alone, for 30 days for epigastric pain syndrome, suggesting SMM has been clinically co-administered with PPIs without documented safety concerns in this observational context. The evidence for a pharmacological interaction (additive, synergistic, or antagonistic) remains insufficiently characterized in prospective, controlled research.
9.5 Relationship to SAM and Methylation Pathways
Since SAM has an inhibitory effect on the system of xenobiotic metabolism in the liver while S-methylmethionine does not affect the functional activity of the liver's isoenzymes and does not have an inhibitory effect on methylation processes, the use of S-methylmethionine is preferable and safe as a nutrient. This is an important distinction from SAMe (S-adenosylmethionine) supplements, which carry a more established pharmacological profile and known interactions.
9.6 Overall Evidence Limitations
S-methylmethionine is a sulfur-containing vitamin-like compound that has been investigated since the 1940s for its gastroprotective and cytoprotective properties. Historically derived from observations of antiulcer activity in plant-derived foods, SMM has been studied in preclinical models and limited clinical settings for its multilevel pharmacological effects. Critically evaluated, the available evidence on SMM's pharmacological actions across organ systems reveals that the most consistently reported gastroprotective and antiulcer effects, as well as antioxidant, anti-inflammatory, cytoprotective, and regenerative activities, are observed predominantly in preclinical studies. Organ-specific protection in the nervous system, liver, kidneys, lungs, skin, eyes, and oral tissues has been described, although human evidence remains scarce.
Research on Vitamin U declined after the rise of more potent pharmaceutical treatments like proton pump inhibitors (PPIs), and it remains of interest in natural medicine and gastrointestinal health formulas. The decline of dedicated clinical research into SMM during the latter decades of the 20th century means that the compound has not been subjected to the scale of randomized controlled trial evidence that modern pharmacology requires for definitive claims.
References
Volver